A first-in-human Phase 1 study to evaluate the safety, tolerability, and pharmacokinetics (PK) of single and multiple ascending doses (SAD and MAD) of BHV-2100.
Latest Information Update: 30 Dec 2024
At a glance
- Drugs BHV-2100 (Primary)
- Indications Migraine; Neuropathic pain
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Biohaven Pharmaceuticals
Most Recent Events
- 08 Jan 2024 Results presented in the finical media release of Biohaven Pharmaceutical Holding Company.
- 08 Jan 2024 Status changed from planning to recruiting.
- 14 Jan 2022 New trial record